Targeted sequencing of 72 prostate cancer driver in 712 plasma cell free DNA samples
Dataset contains targeted sequencing data of 712 plasma cell free DNA samples and 428 white blood cell samples collected from 428 men with metastatic prostate cancer. Target capture was performed using a hydridization-based custom Roche SeqCap EZ Choice kit, designed to capture all exons of 72 prostate cancer driver genes. Cell free DNA was extracted from 10 mL blood samples. Libraries were sequenced using Illumina HiSeq 2500 or Illumina MiSeq instruments to a median coverage of 750x. 62% of samples had ctDNA fraction above 2% of total cfDNA. Note that "Dataset type" is erroneously listed as "Amplicon sequencing", because "Captured-based targeted sequencing" or "Hybridization-based targeted sequencing" were not available options in EGA at the time of submission.
- 1140 samples
- DAC: EGAC00001000962
- Technology: Illumina HiSeq 2500
Data Access Policy for the DNA sequencing study included in the study "Frequent mutation of the FOXA1 untranslated region in prostate cancer"
A data access agreement (DAA), based on the example DAA provided by EGA, is to be filled out by the requester, and then by the data access committee (DAC) for the study "Frequent mutation of the FOXA1 untranslated region in prostate cancer".
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001003113 | Other |